19 Mar

Analysts Are Divided on Johnson & Johnson Stock

WRITTEN BY Margaret Patrick

Analysts’ recommendations and target price

Wall Street analysts have given Johnson & Johnson (JNJ) a 12-month consensus target price of $144.71, 5.50% higher than the company’s closing price on March 18. The consensus analyst recommendation for the stock is a “buy.” Although analysts first revised the company’s target price downward from $145.50 in January to $144.22 in February, they raised it to $144.71 in March.

To learn about the key growth drivers and risks for Johnson & Johnson this year, read Here Are Some Possible Headwinds and Tailwinds for JNJ in 2019.

Analysts Are Divided on Johnson & Johnson Stock

Of the 18 analysts covering Johnson & Johnson, four analysts have given it “strong buys,” five have given it “buys,” eight have given it “holds,” and only one has given it a “sell.” The highest target price estimate for the company is $160, and the lowest is $123.

On March 18, Johnson & Johnson closed at $137.17, 0.31% lower than its previous closing price, 15.64% higher than its 52-week low of $118.62, and 7.93% lower than its 52-week high of $148.99. The company’s market cap is $366.42 billion.

Based on its closing price on March 18, Johnson & Johnson has reported returns of -1.00% in the last week, 2.13% in the last month, and -7.22% in the last quarter. The company has reported returns of -1.94% in the last half year, 3.09% in the last year, and 6.29% year-to-date.

Revenue and EPS estimates

Analysts expect Johnson & Johnson’s revenue to see YoY (year-over-year) changes of -1.94% to $19.62 billion in the first quarter, -1.93% to $20.43 billion in the second quarter, -0.96% to $20.15 billion in the third quarter, and 2.33% to $20.87 billion in the fourth quarter of 2019. Analysts also expect the company’s non-GAAP (generally accepted accounting principles) EPS to see YoY rises of 2.73% to $2.12 in the first quarter, 9.65% to $2.30 in the second quarter, 4.51% to $2.14 in the third quarter, and 2.28% to $2.01 in the fourth quarter.

Analysts expect Johnson & Johnson’s revenues to see YoY changes of -0.50% to $81.17 billion in 2019, 4.18% to $84.56 billion in 2020, and 4.37% to $88.26 billion in 2021. Analysts also expect the company’s non-GAAP EPS to see YoY rises of 4.93% to $8.58 in 2019, 5.76% to $9.08 in 2020, and 7.55% to $9.76 in 2021.

Latest articles

JCPenney (JCP) is slated to announce its results for the first quarter of fiscal 2019, which ended on May 4, on May 21.

17 May

What to Know about the US-China Trade War

WRITTEN BY Mayur Sontakke, CFA, FRM

The key point of contention in the US-China trade dispute is the large trade deficit the United States runs against China.

On May 16, the Labor Department reported jobless claims for last week. Initial jobless claims fell by 16,000 to 212,000 for the week ended May 11.

Jeffrey Gundlach recommended investors take advantage of the volatility in interest rates at the recent Sohn Conference.

Tesla (TSLA) has fallen 4.2% as of 11:55 AM EDT on May 17. While US equity markets opened in the red today, they've recouped their losses.

According to Reuters, on May 16, Vale (VALE) told prosecutors that a dam was at risk of rupturing at its Gongo Soco mine.

172.31.16.229